Inhibition of Placenta Growth Factor Reduces Subretinal Mononuclear Phagocyte Accumulation in Choroidal Neovascularization | Zendy

Sergio CrespoGarcia | Zendy; Caitlin Corkhill | Zendy; Christophe Roubeix | Zendy; AnjaMaria Davids | Zendy; Norbert Kociok | Zendy; Olaf Strauß | Zendy; Antonia M. Joussen | Zendy; Nadine Reichhart | Zendy

Open Access

Inhibition of Placenta Growth Factor Reduces Subretinal Mononuclear Phagocyte Accumulation in Choroidal Neovascularization

Author(s) -

Sergio CrespoGarcia,

Caitlin Corkhill,

Christophe Roubeix,

AnjaMaria Davids,

Norbert Kociok,

Olaf Strauß,

Antonia M. Joussen,

Nadine Reichhart

Publication year - 2017

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.16-21283

Subject(s) - choroidal neovascularization , aflibercept , placental growth factor , vascular endothelial growth factor , medicine , vascular endothelial growth factor a , neovascularization , macrophage polarization , growth factor , downregulation and upregulation , angiogenesis , cancer research , mononuclear phagocyte system , immune system , kinase insert domain receptor , immunology , proinflammatory cytokine , macrophage , bevacizumab , macular degeneration , biology , ophthalmology , receptor , inflammation , vegf receptors , in vitro , biochemistry , chemotherapy , gene

The cellular immune response driven by mononuclear phagocytes (MPs) is crucial for choroidal neovascularization (CNV) progression. Case reports show that a switch from pure anti-vascular endothelial growth factor-A (VEGF-A) intravitreal treatment to aflibercept, a drug with combined anti-VEGF-A and anti-placenta growth factor (PlGF) activity, can be beneficial for patients who do not respond to anti-VEGF-A alone. Since MPs harbor VEGFR1, we hypothesize that the interplay of P1GF/vascular endothelial growth factor receptor 1 (VEGFR1) in immune cells plays a pivotal role for CNV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research